Prescription drug board considering several popular treatments for future cost reviews

A board tasked with reining in prescription drug costs is starting to narrow a list of medications that might be eligible for “cost review,” in hopes of finding ways to bring down expenses for Marylanders on the state’s health plan. The Prescription Drug Affordability Board (PDAB) is considering eight name brand prescription drugs that treat a variety of diseases, including diabetes, HIV, and attention-deficit/hyperactivity disorder (ADHD), to see if those drugs pose an affordability challenge to consumers.